3 results
Approved WMOCompleted
The primary objective of this phase II study is to assess the safety of vismodegib in patients with (inoperable) locally advanced BCC or metastatic BCC.
Approved WMOCompleted
The purpose of this research study is to compare 1 dose (15 ng/kg/minute) of Ularitide with a placebo-substance, to see whether Ularitide is safe and effective for the treatment of acute decompensated heart failure.
Approved WMOCompleted
The primairy objective of this fase II study, is to compare two treatment regimens of vismodegib in two populations of patients with multiple BCC's (patients with Gorlin syndrome and patients who do not have Gorlin syndrome). Primary to assess…